1. World Health Organization. Framework for effective tuberculosis control. WHO/TB/94.179. 1994.
2. Kamolratanakul P, Sawert H, Lertmaharit S et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999;93: 552-557.
3. Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184.
4. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Third edition WHO/CDS/TB/2003.313. 2003.
5. World Health Organization, International Union Against Tuberculosis and Lung Disease. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994;75:180-181.
6. World Health Organization, International Union Against Tuberculosis and Lung Disease. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization. Int J Tuberc Lung Dis 1999; 3:
7. World Health Organization. Essential Drugs. WHO Model List (revised December 1999). WHO Drug Information 1999;13:249-262.
8. Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999;3: S292-S300.
9. Laing RO, McGoldrick KM. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 2000; 4: S194-S207.
10. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001;79: 61-68.
11. Management Sciences for Health. International Drug Price Indicator Guide. accessed on October 13, 2003 at http://erc.msh.org/dmpguide
12. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2003. Geneva, Switzerland, WHO/CDS/TB/2003.316.
13. Blomberg B, Evans P, Phanouvong S et al. Informal consultation on 4-drug fixed-dose combinations compliant with the WHO Model List of Essential Drugs, Geneva, Switzerland, 15-17 August 2001. Geneva: UNDP, World Bank, WHO Special Programme for Research & Training in Tropical Diseases (TDR); 2002. Report No.: TDR/TB/02.1, WHO/CDS/TB/2002.99.
14. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Resp Dis 1989; 140:1618-1622.
15. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-15.
16. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63: 535-553.
17. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954
18. Snider DE, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984;130: 1091-1094.
19. East African and British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils. Lancet 1978;2:8085 334-338.
20. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119: 579-585.
21. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association. Br J Dis Chest 1981;75:141-153.
22. Nunn P, Kibuga D, Gathua S et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;16: 627-30.
23. Pozniak AL, MacLeod GA et al. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. AIDS 1992;6:809-814.
24. Chintu C, Luo C, Bhat G et al. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch Dis Child 1993;68: 665-668.
25. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83: 183-186.